Price$9.60-0.52 (-5.14%)
01:30 PM07:45 PM
News · 26 weeks61-35%
2025-12-142026-06-07
Mix3890d
- Insider13(34%)
- SEC Filings12(32%)
- Other11(29%)
- Leadership1(3%)
- Earnings1(3%)
Latest news
25 items- PRPersonalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection KitsRegulatory milestone for specimen collection kits enables global deployment of Personalis' ultrasensitive MRD detection (Next Personal®) for drug development programs Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that its Personalis EDTA Blood Collection Kit and Personalis cfDNA Blood Collection Kit have obtained Class A CE-IVD marking in compliance with the European Union's In Vitro Diagnostic Regulation (IVDR). The CE Mark represents an important regulatory milestone, ensuring that clinical trial sites throughout the European Union and Great Britain can use these collection kits for interventional studies. These kits are specific
- INSIDERCFO AND COO Tachibana Aaron exercised 40,000 shares at a strike of $9.16 and sold $480,400 worth of shares (40,000 units at $12.01) as part of a pre-agreed trading plan (SEC Form 4)4 - Personalis, Inc. (0001527753) (Issuer)
- SECSEC Form 144 filed by Personalis Inc.144 - Personalis, Inc. (0001527753) (Subject)
- PRPersonalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types Personalis, Inc. (NASDAQ:PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. "Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with Ne
- INSIDERChief Executive Officer Hall Christopher M sold $1,102,000 worth of shares (100,000 units at $11.02) as part of a pre-agreed trading plan and exercised 100,000 shares at a strike of $1.61 (SEC Form 4)4 - Personalis, Inc. (0001527753) (Issuer)
- INSIDERCFO AND COO Tachibana Aaron sold $449,292 worth of shares (38,799 units at $11.58) as part of a pre-agreed trading plan and exercised 38,799 shares at a strike of $9.16 (SEC Form 4)4 - Personalis, Inc. (0001527753) (Issuer)
- SECSEC Form 144 filed by Personalis Inc.144 - Personalis, Inc. (0001527753) (Subject)
- SECSEC Form 144 filed by Personalis Inc.144 - Personalis, Inc. (0001527753) (Subject)
- PRPersonalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx ConsortiumAbstracts span six cancer types, including new data on single-digit parts-per-million ctDNA detection Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that six clinical abstracts demonstrating the broad use of its NeXT Personal® test will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 to June 2 in Chicago. Highlights include an oral podium presentation from the landmark TRACERx study, which demonstrates the clinical impact of NeXT Personal's single-digit parts-per-million (ppm) sensitivity in early-stage non-small cell lung cancer (NSCLC). By detecting circulating tumor DNA (c
- SECPersonalis Inc. filed SEC Form 8-K: Other Events8-K - Personalis, Inc. (0001527753) (Filer)
- PRPersonalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment MonitoringExpanded coverage enables Medicare beneficiaries with Stage II-III TNBC or HER2+ breast cancer to access ultrasensitive MRD testing to monitor response to neoadjuvant therapy Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) has expanded coverage for the company's NeXT Personal minimal residual disease (MRD) test. The new coverage determination is for monitoring treatment response to neoadjuvant therapy (NAT) in patients diagnosed with Stage II-III Triple-Negative Breast Cancer (TNBC) or HER2-positive (HER2+) breast cancer. This decis
- INSIDERDirector Eastham Karin was granted 6,250 shares, increasing direct ownership by 39% to 22,366 units (SEC Form 4)4 - Personalis, Inc. (0001527753) (Issuer)
- INSIDERDirector Bowman A Blaine was granted 6,250 shares, increasing direct ownership by 46% to 19,756 units (SEC Form 4)4 - Personalis, Inc. (0001527753) (Issuer)
- INSIDERDirector Widder Kenneth J was granted 6,250 shares (SEC Form 4)4 - Personalis, Inc. (0001527753) (Issuer)
- INSIDERDirector Shoff Lonnie was granted 6,250 shares, increasing direct ownership by 20% to 37,190 units (SEC Form 4)4 - Personalis, Inc. (0001527753) (Issuer)
- INSIDERDirector Bloom Olivia Kyusuk was granted 6,250 shares, increasing direct ownership by 30% to 27,265 units (SEC Form 4)4 - Personalis, Inc. (0001527753) (Issuer)
- INSIDERDirector Myers Woodrow A Jr was granted 6,250 shares, increasing direct ownership by 24% to 32,366 units (SEC Form 4)4 - Personalis, Inc. (0001527753) (Issuer)
- PRPersonalis to Participate in Upcoming Investor EventsPersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the following investor events: Craig Hallum 23rd Annual Institutional Investor Conference on May 28, 2026 at the Depot Renaissance Hotel in Minneapolis, MN. Jefferies 2026 Global Healthcare Conference on June 3, 2026 at the Marriot Marquis in New York, NY. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-n
- SECPersonalis Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Personalis, Inc. (0001527753) (Filer)
- SECPersonalis Inc. filed SEC Form 8-K: Other Events8-K - Personalis, Inc. (0001527753) (Filer)
- PRPersonalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid TumorsExpanded coverage, supported by published data from the Vall d'Hebron Institute of Oncology (VHIO), enables Medicare beneficiaries receiving immunotherapy to access ultrasensitive MRD testing to monitor treatment response and predict clinical outcomes. Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) has expanded coverage for the company's NeXT Personal minimal residual disease (MRD) test to include immunotherapy monitoring for patients with late-stage solid tumors. This coverage determination is underpinned by landmark clinical evid
- SECSEC Form SCHEDULE 13G filed by Personalis Inc.SCHEDULE 13G - Personalis, Inc. (0001527753) (Subject)
- SECSEC Form S-3ASR filed by Personalis Inc.S-3ASR - Personalis, Inc. (0001527753) (Filer)
- SECSEC Form 10-Q filed by Personalis Inc.10-Q - Personalis, Inc. (0001527753) (Filer)
- SECPersonalis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Personalis, Inc. (0001527753) (Filer)
PSNL FAQ
7 questionsWhat does Personalis Inc. do?
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. The company has partnership with Berry Genomics; Natera, Inc.; and...Where does PSNL stock trade?
Personalis Inc. (PSNL) is listed on NASDAQ.What sector and industry is PSNL in?
Personalis Inc. operates in the Health Care sector, Medical Specialities industry.When did Personalis Inc. go public?
Personalis Inc. (PSNL) completed its IPO in 2019.What are analysts saying about PSNL?
Personalis Inc. has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Equal-Weight with a $1100.00 price target on 2025-12-02.What companies are similar to PSNL?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare PSNL side-by-side with any of them on Quantisnow.How can I track PSNL on Quantisnow?
Quantisnow aggregates Personalis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PSNL to receive live email and push alerts on every new disclosure.